

Supplementary Table S1: Clinical data, medication and blood parameters

	PCS (n=103)	CAD (n=103)	p-value
Clinical data			
Diseases of the circulatory system			
Coronary artery disease, n (%)	4 (3.9)	103 (100)	<0.001
<i>one vessel disease</i>	2 (1.9)	34 (33)	-
<i>two vessel disease</i>	2 (1.9)	40 (38.8)	-
<i>three vessel disease</i>	0 (0)	29 (28.2)	-
STEMI/NSTEMI, n (%)	2 (1.9)	77 (74.8)	<0.001
LVEF^s, %	58.9 ± 4.5	56.3 ± 7.1	0.012
Structural abnormalities^s, n (%)	11 (17.7)	42 (43.4)	<0.001
Cardiac arrhythmia, n (%)	7 (6.8)	11 (10.7)	0.324
<i>Ventricular fibrillation/ flutter</i>	4 (3.9)	10 (9.7)	-
<i>Paroxysmal tachycardia</i>	3 (2.9)	1 (1)	-
Arterial hypertension, n (%)	56 (54.4)	92 (89.3)	<0.001
Pulmonary embolism, n (%)	9 (8.7)	0 (0)	0.002
Endocrine, nutritional or metabolic diseases, n (%)			
<i>Obesity</i>	28 (27.2)	26 (25.2)	0.751
<i>Type 2 diabetes mellitus</i>	14 (13.6)	28 (27.2)	0.015
<i>Other</i>	29 (28.2)	78 (75.7)	<0.001
(Hypo/hyper)thyroidism, n (%)	12 (11.7)	11 (10.7)	0.825
Diseases of the digestive system, n (%)	16 (15.5)	7 (6.8)	0.046
Diseases of the nervous system, n (%)	19 (18.4)	13 (12.6)	0.248
Diseases of the respiratory system, n (%)	40 (38.8)	10 (9.7)	<0.001
Diseases of the musculoskeletal system/ connective tissue, n (%)	64 (62.1)	35 (34)	<0.001
Depressive/ adjustment disorders, n (%)	18 (17.5)	12 (11.7)	0.236
Diseases of the genitourinary system, n (%)	6 (5.8)	7 (6.8)	0.774
Migraine/ headache, n (%)	6 (5.8)	1 (1)	0.055
Medication			
ACE inhibitor	21 (20.4)	61 (59.2)	<0.001
Statin	15 (14.6)	99 (96.1)	<0.001
Beta blocker	34 (33.0)	86 (83.5)	<0.001
AT-II receptor blocker	17 (16.5)	31 (30.1)	0.031
Calcium channel blocker	17 (16.5)	25 (24.3)	0.226
Anticoagulant	21 (20.4)	100 (97.1)	<0.001
Antiarrhythmic	0 (0)	2 (1.9)	0.498
Diuretic	21 (20.4)	22 (21.4)	1.0
Glucocorticoid	17 (16.5)	1 (1.0)	<0.001

Analgesic	34 (33.0)	11 (10.7)	<0.001
Antidepressant	15 (14.6)	7 (6.8)	0.113
Diabetes medication	7 (6.8)	12 (11.7)	0.336
Blood parameters			
Leukocytes, n/nl	6.8 ± 1.8	8.3 ± 2.0	<0.001
Erythrocytes, M/μl	4.9 ± 0.4	4.7 ± 0.5	0.044
Red cell distribution width (RDW), %	13.1 ± 0.9	13.2 ± 1.0	0.436
Hemoglobin, g/dl	14.5 ± 1.4	14.3 ± 1.4	0.323
Hematocrit, %	43.8 ± 3.8	43.5 ± 3.7	0.511
Mean corpuscular volume (MCV), fl	90.3 ± 4.5	92.2 ± 5.3	0.007
Mean corpuscular hemoglobin (MCH), pg	29.9 ± 1.8	30.4 ± 2.1	0.111
Mean cellular hemoglobin concentration (MCHC), g/dl	33.1 ± 0.9	32.9 ± 1.1	0.192
Thrombocytes, n/nl	262.0 ± 64.6	288.1 ± 85.4	0.015
HbA1c, %	6.3 ± 1.5	6.6 ± 1.3	0.373
C-reactive protein, mg/dl	0.4 ± 0.6	0.4 ± 0.4	0.778
Sodium, mmol/l	140.9 ± 2.2	141.6 ± 2.5	0.050
Potassium, mmol/l	4.3 ± 0.4	4.5 ± 0.5	0.003
Creatinine, mg/dl	0.9 ± 0.2	1.0 ± 0.2	<0.001
Urea, mg/dl	30.9 ± 8.8	38.0 ± 9.8	<0.001
eGFR, ml/min/1.73qm	94.2 ± 15.2	86.8 ± 15.0	<0.001
Uric acid, mg/dl	5.8 ± 1.5	6.3 ± 1.5	0.011
Triglycerides, mg/dl	175.0 ± 116.8	156.1 ± 92.9	0.206
Cholesterol, mg/dl	217.9 ± 52.2	158.3 ± 37.9	<0.001
HDL cholesterol, mg/dl	56.1 ± 16.9	45.0 ± 10.4	<0.001
LDL cholesterol, mg/dl	141.2 ± 41.0	96.8 ± 29.1	<0.001
LDL/HDL ratio	2.7 ± 0.9	2.2 ± 0.7	<0.001
Creatin kinase, U/l	155.5 ± 163.8	140.7 ± 241.9	0.611
Glutamate oxalacetate transaminase (GOT), U/l	32.5 ± 14.5	31.1 ± 15.7	0.499
Glutamate pyruvate transaminase (GPT), U/l	40.0 ± 29.1	43.2 ± 28.5	0.424
Gamma glutamyl transferase (gamma GT), U/l	39.6 ± 28.1	49.9 ± 37.0	0.028
Alkaline phosphatase, U/l	80.0 ± 25.7	99.0 ± 37.5	<0.001
Thyroid stimulating hormone (TSH), mIU/l	1.8 ± 1.3	1.9 ± 1.4	0.691

Data presented as mean ± SD or n (%). Between-group comparison was performed using unpaired two-sided t-test or Chi-square test. [§] Determined by echocardiography (n=62 for PCS, n=92 for CAD). LVEF, left ventricular ejection fraction; PCI, percutaneous intervention; PCS, Post-Covid Syndrome; CAD, Coronary Artery Disease. Diseases/ symptoms with a prevalence < 5% are not reported.